nanotech investing Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine Candidate
nanotech investing The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed
nanotech investing Nuvation Bio to Present Pivotal IBTROZI® Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
nanotech investing Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
nanotech investing Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
nanotech investing Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
nanotech investing Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
nanotech investing Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
nanotech investing Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property for Patent Covering Breast Cancer Vaccine Technology
nanotech investing Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
nanotech investing Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
